GlaxoSmithKline Pharmaceuticals Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on GlaxoSmithKline Pharmaceuticals Ltd. from all sources in a single place.

Load latest

GlaxoSmithKline Pharmaceuticals Ltd.

18 Feb 2025

2880.35

1.53%

GlaxoSmithKline share price extends post-Q3 results rally. Jumps 36% in two days

livemint

GlaxoSmithKline share price has surged more than 36% in two sessions after the announcement of Q3 results. The stock has surged 27% in one month and over 17% on a year-to-date (YTD) basis.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 31.66% in the last 3 Months

GlaxoSmithKline Pharmaceuticals Ltd.

17 Feb 2025

2880.35

1.53%

Company Update

GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

As per attachment

pdf

GlaxoSmithKline Pharmaceuticals Ltd.

17 Feb 2025

2880.35

1.53%

Earnings Call

GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

Transcript of Analyst Meet

pdf

GlaxoSmithKline Pharmaceuticals Ltd.

17 Feb 2025

2880.35

1.53%

GlaxoSmithKline Pharmaceuticals shares hits 20% upper circuit as profit jumps fivefold in Q3FY25

livemint

GlaxoSmithKline Pharmaceuticals shares surged 20% to 2,421.30 after a strong Q3FY25 performance, reporting a 400% rise in net profit to 230 crore and 18% revenue growth to 949.42 crore, benefiting from the absence of one-time charges.

GlaxoSmithKline Pharmaceuticals Ltd. has gained 31.66% in the last 3 Months

GlaxoSmithKline hits 20% upper circuit on posting 400% jump in Q3 PAT

Business Standard | 17 Feb 2025

GlaxoSmithKline Pharmaceuticals Ltd.

17 Feb 2025

2880.35

1.53%

GSK Pharma Q3 Review: Motilal Oswal Maintains 'Neutral' Stance On The Stock, Hikes Target Price Here's Why

NDTV Profit

The current valuation captures the earnings upside. hence Motilal Oswal maintains Neutral rating on SGK Pharma.

GlaxoSmithKline Phar.. has an average target of 2630.00 from 2 brokers.

GlaxoSmithKline Pharmaceuticals Ltd.

15 Feb 2025

2880.35

1.53%

Earnings Call

GLAXOSMITHKLINE PHARMACEUTICALS LTD. - 500660 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome

BSE India

as per attachment

pdf

GlaxoSmithKline Pharmaceuticals Ltd.

14 Feb 2025

2880.35

1.53%

GlaxoSmithKline Pharma Q3 results: Net profit up five-fold at Rs 229 crore

Business Standard

GlaxoSmithKline Pharmaceuticals on Friday said its net profit increased over five-fold to Rs 229 crore for the third quarter ended December 31, 2024. The drug firm reported a net profit of Rs 45 crore for the October-December quarter of last fiscal. Revenue from operations rose to Rs 949 crore for the third quarter, as compared to Rs 805 crore in the year-ago period, GlaxoSmithKline Pharmaceuticals said in a statement. "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India," GlaxoSmithKline Pharmaceuticals MD Bhushan Akshikar stated. By focusing on core brands and accelerating digital transformation through innovative go-to-market strategies, the company continues to strengthen its market presence while ensuring broader access to medicines and vaccines, he added. The company saw strong performance across key product portfolios during the quarter, the drug firm said. Flagship brands within the genera